$24.90
2.58% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Janux Therapeutics Inc Stock price

$24.90
-0.43 1.70% 1M
-36.21 59.25% 6M
-28.64 53.49% YTD
-17.47 41.23% 1Y
-0.25 0.99% 5Y
-0.25 0.99% 10Y
-0.25 0.99% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.66 2.58%
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Key metrics

Market capitalization $1.47b
Enterprise Value $459.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 49.18
P/S ratio (TTM) P/S ratio 157.76
P/B ratio (TTM) P/B ratio 1.46
Revenue growth (TTM) Revenue growth 28.12%
Revenue (TTM) Revenue $9.34m
EBIT (operating result TTM) EBIT $-113.58m
Free Cash Flow (TTM) Free Cash Flow $-46.53m
Cash position $1.01b
EPS (TTM) EPS $-1.25
P/E forward negative
P/S forward 1,262.97
EV/Sales forward 393.69
Short interest 26.09%
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Janux Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.34 9.34
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 44 44
61% 61%
466%
- Research and Development Expense 79 79
49% 49%
850%
-112 -112
57% 57%
-1,194%
- Depreciation and Amortization 2.05 2.05
0% 0%
22%
EBIT (Operating Income) EBIT -114 -114
56% 56%
-1,216%
Net Profit -78 -78
40% 40%
-832%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate...
Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2...
Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates.
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 69
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today